Etamzilat (etamsylate) tablets 0.25 №50

Description

Etamzilat Composition
active substance: 1 tablet contains etamsylate 250 mg;

excipients: lactose, monohydrate; corn starch; citric acid, monohydrate; povidone; magnesium stearate.

Etamzilat Dosage form
Pills.

Basic physical and chemical properties: round tablets with a biconvex surface of white or almost white color. Marbling is allowed on the surface of the tablet.

Pharmacotherapeutic group
Antihemorrhagic drugs. Other hemostatic agents for systemic use. ATX code B02B X01.

Pharmacodynamics
Etamsylate is an agent for the prevention and control of bleeding. It affects the first stage of the hemostasis mechanism (the interaction between endothelium and platelets).

The drug increases the adhesion of platelets, normalizes the stability of the capillary walls, thus reducing their permeability, inhibits the biosynthesis of prostaglandins, which cause platelet disaggregation, vasodilation and increased capillary permeability. As a result, bleeding time is significantly reduced, blood loss is reduced.

Pharmacokinetics
Etamsylate is almost completely absorbed in the gastrointestinal tract, reaching peak serum concentrations 4 hours after ingestion. About 95% of the drug binds to plasma proteins.

Approximately 72% of the administered dose is excreted unchanged in the urine within the first 24 hours. Etamsylate crosses the placental barrier. It is not known whether etamsylate passes into breast milk.

Etamzilat Indications
Prevention and control of hemorrhages in the superficial and internal capillaries of various etiologies, especially if the bleeding is caused by damage to the endothelium:

prevention and treatment of bleeding during and after surgery in otolaryngology, gynecology, obstetrics, urology, dentistry, ophthalmology and plastic surgery;
prevention and treatment of capillary bleeding of various etiology and localization: hematuria, metrorrhagia, primary hypermenorrhea, hypermenorrhea in women with intrauterine contraceptives, epistaxis, bleeding of the gums.
Contraindications
Hypersensitivity to etamsylate or to any other component of the drug. Acute porphyria, increased blood clotting, thrombosis, thromboembolism. Hemoblastosis (lymphatic and myeloid leukemia, osteosarcoma) in children.

Interaction with other medicinal products and other types of interactions
Taking etamsylate before the introduction of dextrans (for example, reopolyglucin) prevents their antiaggregatory effect, after the introduction of the latter, it does not have a hemostatic effect. Interaction with aminocaproic acid, vicasol is allowed.

Application features
Use with caution in patients who have previously had thrombosis or thromboembolism. The drug is ineffective with a reduced platelet count.

For hemorrhagic complications associated with an overdose of anticoagulants, it is recommended to use specific antidotes.

Before starting treatment, other causes of bleeding should be ruled out.

If Etamsilat-KB is used to reduce excessive and / or prolonged menstrual bleeding and no improvement is observed, possible pathological causes (for example, the presence of fibrous uterine formations) should be excluded.

In case of skin reactions or fever, treatment should be discontinued and the doctor should be informed, as this may be a sign of hypersensitivity.

The drug contains lactose, so it should not be prescribed to patients with rare hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption syndrome.

Use in patients with renal insufficiency.

The safety and efficacy of ethamsylate has not been studied in patients with renal impairment. Since etamsylate is almost completely excreted by the kidneys, the dose of the drug should be reduced in case of renal failure.

Laboratory tests.

At therapeutic doses, ethamsylate can reduce the performance of the creatinine test.